Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Investigational new drugs

• Publication date

  2013-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10637-012-9815-9PMID 22492020PMCID PMC3715080
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting the checkpoint kinase Chk1 in cancer therapy

  2010cited by this paper
• Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC).

  2010cited by this paper
• New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network

  2010cited by this paper
• 201 Evaluation of the antitumor activity of pemetrexed in combination with the Chk1 inhibitor LY2603618

  2010cited by this paper
• Abstract B248: Characterization and preclinical development of LCI‐1, a selective and potent Chk1 inhibitor in phase 1 clinical trials

  2009cited by this paper
• Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer.

  2009cited by this paper
• A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas

  2009cited by this paper
• A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer.

  2008cited by this paper
• Chk1 Haploinsufficiency Results in Anemia and Defective Erythropoiesis

  2008cited by this paper
• Targeting Checkpoint Kinase 1 in Cancer Therapeutics

  2007cited by this paper
• Gemcitabine-Induced Activation of Checkpoint Signaling Pathways That Affect Tumor Cell Survival

  2005cited by this paper
• FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer.

  2005cited by this paper
• Pemetrexed: a multitargeted antifolate.

  2005cited by this paper
• Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine.

  2005cited by this paper
• Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints

  2002cited by this paper
• Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint.

  2000cited by this paper
• Essential role of BETA2/NeuroD1 in development of the vestibular and auditory systems.

  2000cited by this paper
• Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.

  2000cited by this paper
• Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer.

  2000cited by this paper
• Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.

  1999cited by this paper
• Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25.

  1997cited by this paper
• Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis

  1997cited by this paper

• Targeting the DNA damage response prevents regrowth of colorectal peritoneal metastasis-derived organoids following treatment with mitomycin C

  2026cites this paper
• Inhibition of replication factor C4-induced DNA damage repair reverses the chemoresistance of glioblastoma to temozolomide and reveals the synthetic lethal effect of combined targeting of checkpoint kinase 1.

  2026cites this paper
• Revisiting CHK1 and WEE1 kinases as therapeutic targets in cancer.

  2025cites this paper
• Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy

  2022cites this paper
• Effective drug combinations in breast, colon and pancreatic cancer cells

  2022cites this paper
• Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer

  2021cites this paper
• Chk1 and the Host Cell DNA Damage Response as a Potential Antiviral Target in BK Polyomavirus Infection

  2021cites this paper
• CHK1 inhibitor sensitizes resistant colorectal cancer stem cells to nortopsentin

  2021cites this paper
• The Atr-Chek1 pathway inhibits axon regeneration in response to Piezo-dependent mechanosensation

  2020cites this paper
• Gene Therapy in Oncology

  2020cites this paper
• Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo

  2019cites this paper
• Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death

  2019cites this paper
• Targeting CHK1 for Cancer Therapy: Rationale, Progress and Prospects

  2018cites this paper
• Clinical Development of CHK1 Inhibitors

  2018cites this paper
• Nouvelles perspectives dans le ciblage thérapeutique de la réparation de l’ADN

  2017cites this paper
• [DNA repair as a therapeutic target].

  2017cites this paper
• A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients

  2017cites this paper
• Selective Kinase Inhibitors in Cancer

  2017cites this paper
• Achieving Precision Death with Cell-Cycle Inhibitors that Target DNA Replication and Repair

  2017cites this paper
• A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.

  2017cites this paper
• ATR/CHK1 inhibitors and cancer therapy.

  2017cites this paper
• Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent

  2017cites this paper
• Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors

  2016cites this paper
• Cell Cycle Kinases in Osteosarcoma: Potential for Therapeutic Intervention.

  2016cites this paper
• LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models

  2016cites this paper
• DNA repair targeted therapy: The past or future of cancer treatment?

  2016cites this paper
• Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer

  2016cites this paper
• DNA Repair Pathways as a Potential Target for Radiosensitization

  2016cites this paper
• Etude de nouvelles fonctions de la protéine checkpoint kinase 1 (Chk1) au cours de la différenciation myéloïde normale et leucémique

  2016cites this paper
• Novel and Emerging Targeted Therapies of Colorectal Cancer.

  2015cites this paper
• Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors

  2015cites this paper
• Aven‐mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma

  2015cites this paper
• Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells

  2015cites this paper
• A novelly synthesized phenanthroline derivative is a promising DNA-damaging anticancer agent inhibiting G1/S checkpoint transition and inducing cell apoptosis in cancer cells

  2015cites this paper
• An evaluation of the checkpoint kinase inhibitor V158411

  2015cites this paper
• Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients

  2015cites this paper
• Identification of novel aminothiazole and aminothiadiazole conjugated cyanopyridines as selective CHK1 inhibitors.

  2015cites this paper
• Targeting the Checkpoint to Kill Cancer Cells

  2015cites this paper
• Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy

  2015cites this paper
• Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design

  2015cites this paper
• Development of Synthetic Lethality Anticancer Therapeutics

  2014cites this paper
• Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor

  2014cites this paper
• Chemotherapeutic Compounds Targeting the DNA Double-Strand Break Repair Pathways: The Good, the Bad, and the Promising

  2014cites this paper
• γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments

  2014cites this paper
• Cell cycle inhibitors for the treatment of NSCLC

  2014cites this paper
• Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer

  2014cites this paper
• CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy.

  2014cites this paper
• Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer

  2014cites this paper
• Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors

  2014cites this paper
• Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors.

  2014cites this paper
• Structure-based design , discovery and development of checkpoint kinase inhibitors as potential anti-cancer therapies

  2014cites this paper
• The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells

  2014cites this paper
• Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies

  2013cites this paper
• Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy.

  2013cites this paper
• Kinase Inhibitors in Cancer

  2013cites this paper
• Panobinostat Synergistically Enhances the Cytotoxic Effects of Cisplatin, Doxorubicin or Etoposide on High-Risk Neuroblastoma Cells

  2013cites this paper
• Targeting Stem Cells

  2013cites this paper
• Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo

  2013cites this paper
• PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells

  2013cites this paper
• Screening of biomarkers for lung cancer with gene expression profiling data.

  2013cites this paper
• Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors

  2012cites this paper